Patients taking the highest dose of amycretin experienced a mean weight loss of 22% after 36 weeks. By contrast, those taking a placebo experienced weight gain of ... Wegovy and Eli Lilly's ...

Eli Lilly expects to read out results from a study in people with obesity and osteoarthritis of the knee in 2025.

"Fire Your Tax Advisor" After He Was Told To Switch From A Roth To A Traditional 401(k) For Tax Deduction This Magnificent Artificial Intelligence (AI) Stock Has Shot Up Over 175% in Just 3 Months ...

US-based pharmaceutical company Eli Lilly is planning to launch Mounjaro, an anti-diabetes and weight loss drug in India by 2025 after regulatory approvals, reported News18 citing officials from ...

After adjusting for one-time costs, Eli Lilly's adjusted earnings per share (EPS) of $5.32 topped expectations of $5.11. Sales of the company's blockbuster weight-loss drugs Mounjaro and Zepbound ...

Weight loss drugs are huge these days, and Eli Lilly (LLY) is leading the pack when it comes to these. However, today’s leader can become tomorrow’s laggard without continuous development ...

Analysts tracking the company see increased sales and profit for Eli Lilly in the first full period in which its weight-loss drugs ceased to be in shortage. The results come after the maker of ...

Retatrutide is a key part of Eli Lilly's drug pipeline that could help the company maintain its dominance in the blockbuster weight loss and diabetes treatment space and gain an edge over key ...